Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aceragen Inc's Business Segments
Aceragen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 2
Regions Reported
-
Aceragen Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Defense Threat Reduction Agency Award Products97.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Defense Threat Reduction Agency Award Products | $ 2 | 97.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Aceragen Inc
Aceragen Inc is a biotechnology company that specializes in the development and commercialization of innovative gene therapies. The company is dedicated to addressing unmet medical needs and improving patient outcomes through cutting-edge genetic technologies.
Founded in , Aceragen has emerged as a leading player in the field of gene therapy. The company's team consists of highly skilled scientists, researchers, and experts in the field of genetics, molecular biology, and clinical development. They bring together their diverse expertise to create advanced therapies that have the potential to revolutionize the treatment of various genetic disorders.
Aceragen's primary focus is on developing gene therapies for rare genetic diseases with limited or no treatment options available. These diseases often result from single gene mutations that lead to significant health issues. By using state-of-the-art gene editing and gene delivery techniques, Aceragen aims to correct these mutations and restore normal cellular function, thereby providing long-lasting and potentially curative treatments.
The company's proprietary platform technology allows for precise editing of specific genes, enabling targeted therapies that have minimal off-target effects. This approach ensures the safety and efficacy of the developed therapies, which are rigorously tested in preclinical and clinical studies before regulatory approval and commercialization.
Aceragen's gene therapies are designed to be delivered directly to the affected cells or tissues in order to maximize their therapeutic potential. The company utilizes various delivery methods, including viral vectors, nanoparticles, and exosomes, to efficiently and selectively deliver the therapeutic genes to the desired locations.
In addition to developing gene therapies, Aceragen also conducts extensive research and collaborations to advance the understanding of genetic diseases and improve the overall field of gene therapy. They collaborate with academic institutions, research organizations, and other biotechnology companies to exchange knowledge, share resources, and accelerate the development of transformative treatments.
Furthermore, Aceragen actively participates in regulatory discussions and engages with patient advocacy groups to ensure the patient perspective is considered in the drug development process. This patient-centric approach reflects the company's commitment to developing therapies that meet the specific needs and challenges faced by patients with genetic disorders.
Overall, Aceragen Inc is driven by a passion for innovation and a desire to make a meaningful impact on the lives of patients suffering from genetic diseases. Through their cutting-edge technology, rigorous research, and strategic collaborations, the company strives to bring transformative gene therapies to the clinic and provide hope to those in need.
Founded in , Aceragen has emerged as a leading player in the field of gene therapy. The company's team consists of highly skilled scientists, researchers, and experts in the field of genetics, molecular biology, and clinical development. They bring together their diverse expertise to create advanced therapies that have the potential to revolutionize the treatment of various genetic disorders.
Aceragen's primary focus is on developing gene therapies for rare genetic diseases with limited or no treatment options available. These diseases often result from single gene mutations that lead to significant health issues. By using state-of-the-art gene editing and gene delivery techniques, Aceragen aims to correct these mutations and restore normal cellular function, thereby providing long-lasting and potentially curative treatments.
The company's proprietary platform technology allows for precise editing of specific genes, enabling targeted therapies that have minimal off-target effects. This approach ensures the safety and efficacy of the developed therapies, which are rigorously tested in preclinical and clinical studies before regulatory approval and commercialization.
Aceragen's gene therapies are designed to be delivered directly to the affected cells or tissues in order to maximize their therapeutic potential. The company utilizes various delivery methods, including viral vectors, nanoparticles, and exosomes, to efficiently and selectively deliver the therapeutic genes to the desired locations.
In addition to developing gene therapies, Aceragen also conducts extensive research and collaborations to advance the understanding of genetic diseases and improve the overall field of gene therapy. They collaborate with academic institutions, research organizations, and other biotechnology companies to exchange knowledge, share resources, and accelerate the development of transformative treatments.
Furthermore, Aceragen actively participates in regulatory discussions and engages with patient advocacy groups to ensure the patient perspective is considered in the drug development process. This patient-centric approach reflects the company's commitment to developing therapies that meet the specific needs and challenges faced by patients with genetic disorders.
Overall, Aceragen Inc is driven by a passion for innovation and a desire to make a meaningful impact on the lives of patients suffering from genetic diseases. Through their cutting-edge technology, rigorous research, and strategic collaborations, the company strives to bring transformative gene therapies to the clinic and provide hope to those in need.
Aceragen Inc is a biotechnology company dedicated to pioneering advanced therapies for rare genetic diseases. The companys focus on these conditions reflects its commitment to addressing unmet medical needs in a specialized healthcare sector. Below is an extensive overview of the segments, products, and services offered by Aceragen Inc.
Segments:
1. Genetic Testing:
Aceragen Inc provides an array of genetic testing services that play a crucial role in the diagnosis and management of rare genetic diseases. The genetic testing capabilities include whole exome sequencing, targeted next-generation sequencing, and other cutting-edge methodologies. Through these tests, the company analyzes patients genetic material to detect mutations, polymorphisms, and chromosomal anomalies. This segment not only helps in diagnosing diseases but also in identifying carrier status and guiding treatment strategies.
2. Drug Development:
The drug development segment is the cornerstone of Aceragen Incs operations. The company engages in rigorous research and development aimed at creating groundbreaking therapies tailored for specific genetic mutations that lead to rare diseases. This process involves extensive preclinical studies, high-throughput screening, and the development of pharmacodynamic models to guide the selection of the most promising candidates for further clinical evaluation. The company maintains a pipeline of investigational drugs that are designed to restore normal function at the molecular level.
Products:
1. Diagnostic Kits:
Aceragen Inc develops and markets diagnostic kits formulated to facilitate the rapid and accurate identification of rare genetic diseases. These kits typically include reagents, controls, and comprehensive protocols that empower healthcare professionals to conduct genetic tests in clinical settings. Additionally, the kits are designed to be user-friendly and compliant with regulatory standards, ensuring reliable results that can aid in clinical decision-making.
2. Therapeutic Drugs:
This product line includes several investigational drugs that target specific genetic anomalies identified in rare diseases. These therapeutic agents are often categorized into small molecules, gene therapies, and biologics. By addressing the root cause of genetic disorders, these drugs aim to halt disease progression and improve patient outcomes. Aceragen Inc actively engages in formulation and delivery optimization to enhance therapeutic efficacy and patient adherence.
Services:
1. Genetic Counseling:
Aceragen Inc provides genetic counseling services to patients and their families grappling with the complexities of rare genetic diseases. The genetic counseling team consists of certified professionals who offer personalized consultations to discuss testing options, interpret results, and navigate the implications of genetic findings on health and family planning. The counseling process ensures that patients make informed decisions while receiving emotional support throughout their journey.
2. Clinical Trials:
As part of its commitment to advancing therapeutic options, Aceragen Inc conducts a range of clinical trials across different phases. By enrolling patients with rare genetic conditions, the company tests the safety, tolerability, and efficacy of its investigational drugs. The trials are often designed to fulfill regulatory requirements for drug approval and contribute to the overall understanding of rare diseases. Participants gain access to novel therapies, often before they are available on the market.
3. Educational Programs:
Aceragen Inc recognizes the importance of education in the realm of rare diseases. The company organizes various educational initiatives, including workshops, webinars, and seminars aimed at healthcare providers, patients, and advocacy groups. These programs focus on the latest advancements in genetic research, diagnostic techniques, and treatment options, promoting awareness and early diagnosis of rare genetic conditions.
4. Collaborations and Partnerships:
The company actively seeks collaborations with academic entities, research institutions, and other pharmaceutical companies to leverage expertise and resources. Such partnerships enhance research capabilities and expedite the drug development process. By engaging in strategic alliances, Aceragen Inc aims to pool knowledge, share findings, and ultimately fast-track innovative solutions to address the needs of patients suffering from rare diseases.
Conclusion:
In summary, Aceragen Inc stands at the forefront of biotechnology innovation, focusing on rare genetic diseases through a robust portfolio of segments, products, and services. From comprehensive genetic testing and advanced drug development to support services like genetic counseling and educational programs, the company is dedicated to improving the quality of life for patients affected by rare conditions. By fostering collaborations and driving research initiatives, Aceragen Inc is poised to make significant contributions to the field of genetic medicine.
Segments:
1. Genetic Testing:
Aceragen Inc provides an array of genetic testing services that play a crucial role in the diagnosis and management of rare genetic diseases. The genetic testing capabilities include whole exome sequencing, targeted next-generation sequencing, and other cutting-edge methodologies. Through these tests, the company analyzes patients genetic material to detect mutations, polymorphisms, and chromosomal anomalies. This segment not only helps in diagnosing diseases but also in identifying carrier status and guiding treatment strategies.
2. Drug Development:
The drug development segment is the cornerstone of Aceragen Incs operations. The company engages in rigorous research and development aimed at creating groundbreaking therapies tailored for specific genetic mutations that lead to rare diseases. This process involves extensive preclinical studies, high-throughput screening, and the development of pharmacodynamic models to guide the selection of the most promising candidates for further clinical evaluation. The company maintains a pipeline of investigational drugs that are designed to restore normal function at the molecular level.
Products:
1. Diagnostic Kits:
Aceragen Inc develops and markets diagnostic kits formulated to facilitate the rapid and accurate identification of rare genetic diseases. These kits typically include reagents, controls, and comprehensive protocols that empower healthcare professionals to conduct genetic tests in clinical settings. Additionally, the kits are designed to be user-friendly and compliant with regulatory standards, ensuring reliable results that can aid in clinical decision-making.
2. Therapeutic Drugs:
This product line includes several investigational drugs that target specific genetic anomalies identified in rare diseases. These therapeutic agents are often categorized into small molecules, gene therapies, and biologics. By addressing the root cause of genetic disorders, these drugs aim to halt disease progression and improve patient outcomes. Aceragen Inc actively engages in formulation and delivery optimization to enhance therapeutic efficacy and patient adherence.
Services:
1. Genetic Counseling:
Aceragen Inc provides genetic counseling services to patients and their families grappling with the complexities of rare genetic diseases. The genetic counseling team consists of certified professionals who offer personalized consultations to discuss testing options, interpret results, and navigate the implications of genetic findings on health and family planning. The counseling process ensures that patients make informed decisions while receiving emotional support throughout their journey.
2. Clinical Trials:
As part of its commitment to advancing therapeutic options, Aceragen Inc conducts a range of clinical trials across different phases. By enrolling patients with rare genetic conditions, the company tests the safety, tolerability, and efficacy of its investigational drugs. The trials are often designed to fulfill regulatory requirements for drug approval and contribute to the overall understanding of rare diseases. Participants gain access to novel therapies, often before they are available on the market.
3. Educational Programs:
Aceragen Inc recognizes the importance of education in the realm of rare diseases. The company organizes various educational initiatives, including workshops, webinars, and seminars aimed at healthcare providers, patients, and advocacy groups. These programs focus on the latest advancements in genetic research, diagnostic techniques, and treatment options, promoting awareness and early diagnosis of rare genetic conditions.
4. Collaborations and Partnerships:
The company actively seeks collaborations with academic entities, research institutions, and other pharmaceutical companies to leverage expertise and resources. Such partnerships enhance research capabilities and expedite the drug development process. By engaging in strategic alliances, Aceragen Inc aims to pool knowledge, share findings, and ultimately fast-track innovative solutions to address the needs of patients suffering from rare diseases.
Conclusion:
In summary, Aceragen Inc stands at the forefront of biotechnology innovation, focusing on rare genetic diseases through a robust portfolio of segments, products, and services. From comprehensive genetic testing and advanced drug development to support services like genetic counseling and educational programs, the company is dedicated to improving the quality of life for patients affected by rare conditions. By fostering collaborations and driving research initiatives, Aceragen Inc is poised to make significant contributions to the field of genetic medicine.